Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression

@article{Uhr2008PolymorphismsIT,
  title={Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression},
  author={Manfred Uhr and Alina Tontsch and Christian Namendorf and Stephan Ripke and Susanne Lucae and Marcus Ising and Tatjana Dose and Martin Ebinger and Marcus C. Rosenhagen and Martin A. Kohli and Stefan Kloiber and Daria Salyakina and Thomas Bettecken and Michael Specht and Benno P{\"u}tz and Elisabeth B. Binder and Bertram M{\"u}ller-Myhsok and Florian Holsboer},
  journal={Neuron},
  year={2008},
  volume={57},
  pages={203-209}
}

Figures and Tables from this paper

ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression
TLDR
This study provides confirmation that certain ABCB1 polymorphisms predict response to substrate medications in geriatric patients and replicates the published findings of others.
ABCB1 genotyping in the treatment of depression.
TLDR
32 studies investigating the question of whether ABCB1 polymorphisms predict clinical efficacy and/or tolerability of antidepressants in humans are summarized and the clinical application status ofABCB1 genotyping in depression treatment is evaluated.
ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment
TLDR
It is suggested that single nucleotide polymorphisms in the ABCB1 gene may be indicators of the severity of depression and of the likely S-CIT treatment remission response in MDD.
The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study
TLDR
It is suggested that antidepressant treatment of depression can be optimized by the clinical application of ABCB1 genotypes, and patients carrying the TT/GG genotype seemed to benefit from an increase in P-gp substrate dose.
ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder
TLDR
It is concluded that adverse drug effects with SSRI treatment, in particular serotonergic effects, are predicted by two common polymorphisms of the ABCB1 gene.
MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression
Association between ABCB1 Polymorphisms and Antidepressant Treatment Response in Taiwanese Major Depressive Patients
TLDR
Investigation of possible associations of functional ABCB1 polymorphisms with response to antidepressant treatment and serum cortisol levels in Taiwanese patients with major depressive disorder suggested that the variants ofABCB1 may influence the short-term antidepressant response in MDD patients.
ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
TLDR
The data suggest that antidepressant dose needed to remit can be predicted by an ABCB1 SNP, which has the potential clinical translation implications for dose selection and remission from MDD.
Pharmacogenomics in Psychiatric Disorders
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.
TLDR
There is a compelling case for a key role of HTR2A in the mechanism of antidepressant action, as detected in patients treated with the antidepressant citalopram.
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs.
Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-Glycoprotein gene disruption
Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.
TLDR
Clinical studies on the effects of C3435T on MDR1 expression and function in the tissues, and also on the pharmacokinetics and pharmacodynamics have been performed around the world; however, there are still discrepancies in the results, suggesting that the haplotype analysis of the gene should be included instead of SNP detection, and the design of clinical trials must be carefully planned to avoid misinterpretations.
Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment
TLDR
It is proposed that the FKBP5 variant–dependent alterations in HPA-axis regulation could be related to the faster response to antidepressant drug treatment and the increased recurrence of depressive episodes observed in this subgroup of depressed individuals.
abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice.
Genomic evidence for recent positive selection at the human MDR1 gene locus.
TLDR
Detailed characterization of the haplotype and linkage disequilibrium architecture of the entire 200 kb of the MDR1 gene in five world populations, namely, Chinese, Malays, Indians, Caucasians and African-Americans finds statistically significant evidence of recent positive selection for the e21/2677T and e26/3435T alleles in the Chinese population, and for the E26/ 3435T allele in the Malay population.
Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects
P‐glycoprotein, the gene product of MDR1, confers multidrug resistance against antineoplastic agents but also plays an important role in the bioavailability of common drugs in medical treatment.
P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline
TLDR
It is confirmed that P-gp plays an important role in the interaction between CNS drugs and the blood–brain barrier and clinical studies showing different side-effects in patients with P- gp polymorphisms confirm the clinical importance of these findings.
...
1
2
3
4
...